Ligand Pharmaceuticals
Builds biopharmaceutical royalty portfolios and licenses Captisol and NITRICIL drug technologies.
$280.49
After-hours close−0.11 (−0.04%)
At close$280.60(−1.38%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | $2.30 | — | — |
| Aug 2026 | $2.01 | $2.37 | +17.9% |
| May 2026 | $1.84 | $1.63 | −11.4% |
| Feb 2026 | $1.46 | $2.02 | +38.4% |
| Nov 2025 | $1.97 | $3.09 | +56.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Jul 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Oct 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | $2.30 | — | — | $78.1M | — | — |
| Aug 6, 2026 | $2.01 | $2.37 | +17.9% | $61.3M | $63.7M | +3.9% |
| May 14, 2026 | $1.84 | $1.63 | −11.4% | $59.1M | $51.7M | −12.5% |
| Feb 26, 2026 | $1.46 | $2.02 | +38.4% | $55.6M | $59.7M | +7.3% |
| Nov 6, 2025 | $1.97 | $3.09 | +56.9% | $55.6M | $115.5M | +107.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 7, 2024 | ||||||
| Feb 27, 2024 | ||||||
| Nov 8, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 4, 2023 | ||||||
| Feb 22, 2023 | ||||||
| Nov 7, 2022 | ||||||
| Aug 8, 2022 | ||||||
| May 4, 2022 | ||||||
| Feb 17, 2022 | ||||||
| Nov 9, 2021 | ||||||
| Jul 29, 2021 | ||||||
| May 3, 2021 | ||||||
| Feb 3, 2021 | ||||||
| Oct 30, 2020 | ||||||
| Aug 3, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 6, 2020 | ||||||
| Nov 5, 2019 | ||||||
| Jul 30, 2019 | ||||||
| May 2, 2019 | ||||||
| Feb 7, 2019 | ||||||
| Nov 8, 2018 | ||||||
| Aug 6, 2018 | ||||||
| May 8, 2018 | ||||||
| Feb 21, 2018 | ||||||
| Nov 9, 2017 | ||||||
| Aug 7, 2017 | ||||||
| May 9, 2017 | ||||||
| Feb 23, 2017 | ||||||
| Nov 3, 2016 | ||||||
| Aug 4, 2016 | ||||||
| May 4, 2016 | ||||||
| Feb 10, 2016 | ||||||
| Nov 9, 2015 | ||||||
| Aug 4, 2015 | ||||||